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Abstract
Background: While there is some consensus on methods for investigating statistical and methodological
heterogeneity, little attention has been paid to clinical aspects of heterogeneity. The objective of this study is to
summarize and collate suggested methods for investigating clinical heterogeneity in systematic reviews.
Methods: We searched databases (Medline, EMBASE, CINAHL, Cochrane Library, and CONSORT, to December 2010)
and reference lists and contacted experts to identify resources providing suggestions for investigating clinical
heterogeneity between controlled clinical trials included in systematic reviews. We extracted recommendations,
assessed resources for risk of bias, and collated the recommendations.
Results: One hundred and one resources were collected, including narrative reviews, methodological reviews,
statistical methods papers, and textbooks. These resources generally had a low risk of bias, but there was minimal
consensus among them. Resources suggested that planned investigations of clinical heterogeneity should be made
explicit in the protocol of the review; clinical experts should be included on the review team; a set of clinical
covariates should be chosen considering variables from the participant level, intervention level, outcome level,
research setting, or others unique to the research question; covariates should have a clear scientific rationale; there
should be a sufficient number of trials per covariate; and results of any such investigations should be interpreted
with caution.
Conclusions: Though the consensus was minimal, there were many recommendations in the literature for
investigating clinical heterogeneity in systematic reviews. Formal recommendations for investigating clinical
heterogeneity in systematic reviews of controlled trials are required.
Background
Systematic reviews sometimes apply statistical techni-
ques to combine data from multiple studies resulting in
a meta-analysis. Meta-analyses result in a point estimate,
the summary treatment effect, together with a measure
of the precision of results (e.g., a 95% confidence inter-
val). These measures of precision represent the degree of
variability or heterogeneity in the results among
included studies. There are several possible sources of
variability or heterogeneity among studies that are
included in meta-analyses. Variability in the participants,
the types or timing of outcome measurements, and
intervention characteristics may be termed clinical het-
erogeneity; variability in the trial design and quality is
typically termed methodological heterogeneity; variabil-
ity in summary treatment effects between trials is
termed statistical heterogeneity [1]. Methodological and
clinical sources of heterogeneity contribute to the mag-
nitude and presence of statistical heterogeneity [1].
Methodological heterogeneity hinges on aspects of im-
plementation of the individual trials and how they differ
from each other. For example, trials that do not ad-
equately conceal allocation to treatment groups may re-
sult in overestimates in the meta-analytic treatment
effects [2]. Significant statistical heterogeneity arising
from methodological heterogeneity suggests that the
studies are not all estimating the same effects due to dif-
ferent degrees of bias.
* Correspondence: jgagnier@umich.edu
1Departments of Orthopaedic Surgery and Epidemiology, University of
Michigan, 24 Frank Lloyd Wright Drive, Ann Arbor, MI, USA
Full list of author information is available at the end of the article
© 2012 Gagnier et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Gagnier et al. BMC Medical Research Methodology 2012, 12:111
http://www.biomedcentral.com/1471-2288/12/111
Clinical heterogeneity arises from differences in par-
ticipant characteristics (e.g., sex, age, baseline disease se-
verity, ethnicity, comorbidities), types or timing of
outcome measurements, and intervention characteristics
(e.g., dose and frequency of dose [1]). This heterogeneity
can cause significant statistical heterogeneity, inaccurate
summary effects and associated conclusions, misleading
decision makers and others. As such, systematic
reviewers need to consider how best to handle sources
of heterogeneity [1]. For example, preplanned subgroup
analyses, stratifying for similar characteristics of the
intervention and participants, could tease-out important
scientific and clinically relevant information [3].
Systematic reviews are frequently recognized as the
best available evidence for decisions about health-care
management and policy [3-7]. Results of systematic
reviews are often incorporated into clinical practice
guidelines [5] and required in funding applications by
granting agencies [6]. In spite of all this it appears
health-care professionals and policy makers infrequently
use systematic reviews to guide decision-making [8].
A limitation of many systematic reviews is that their
content and format are frequently not useful to decision
makers [8]. For example, while some guidance exists de-
scribing what to include in reports of systematic reviews
(e.g., the PRISMA statement [9]), characteristics of the
intervention that are necessary to apply their findings
are infrequently provided [10-13]. This has led to some
preliminary work on how to extract clinically relevant
information from systematic reviews [14]. Furthermore,
systematic reviews commonly show substantial hetero-
geneity in estimated effects (statistical heterogeneity),
possibly due to methodological, clinical or unknown fea-
tures in the included trials [15]. While guidance exists
on the assessment and investigation of methodological
[1] and statistical heterogeneity [1,16], little attention
has been given to clinical heterogeneity.
We report a systematic review of suggested methods
for investigating clinical heterogeneity in systematic
reviews of controlled clinical trials. We also provide
some guidance for systematic reviewers.
Methods
This project identified resources giving recommenda-
tions for investigating clinical heterogeneity in systematic
reviews. We extracted their recommendations, assessed
their risk for bias, and categorized and described the
suggestions.
Search
The following databases were searched: Medline (to
October 29, 2010), EMBASE (to Oct 30, 2010), CINAHL
(1981 to Oct 30, 2010), Health Technology Assessment
(to Oct 29, 2010), the Cochrane Methodology Register
(to Oct 29, 2010), and the CONSORT database of meth-
odological papers (to October 30, 2010). A library and in-
formation scientist was consulted to create sensitive and
specific searches, combining appropriate terms and
extracting new terms from relevant studies for each data-
base. The following search terms were used in the vari-
ous databases and at various stages of the search:
heterogeneity, applicability, clinical, assessment, check-
list, guideline(s), scale, and criteria. The “adjacent” or
“within X words” tools were used for the terms “clinical”
and “heterogeneity” for all databases. In addition, we
used the PubMed related-links option that identifies
indexed studies on similar topics or having similar index-
ing terms to include a broad range of papers that might
be indirectly related to clinical heterogeneity. Appendix
A contains details of the electronic searching. One inves-
tigator (JG) contacted representatives of the Cochrane
Collaboration, the Campbell Collaboration, the Agency
for Healthcare Research and Quality (AHRQ) and a se-
lection of experts identified through an initial review of
the literature to suggest relevant articles, guidelines, pos-
ition papers, textbooks or other experts in the area. We
also reviewed the Cochrane Handbook, the Campbell
Collaboration methods guides, and the AHRQ compara-
tive effectiveness section for any guidance on clinical het-
erogeneity and searched reference lists of all retrieved
resources.
The overall process consisted of a “snowballing” tech-
nique of seeking information on the topic, by which we
asked experts to refer us to other experts or resources,
and so on, until each new resource yielded a negligible
return. Several individuals with expertise in the area of
systematic reviews (JG, DM, JB, CB) met to identify key
textbooks to include out of thier personal knowledge of
textbooks in the area. These individuals presented what
each felt were key textbooks in the area and then
debated the merits of each, finally coming to a
consensus-based decision on which to include. In gen-
eral, these methods allowed us to include a broad array
of resources related to investigating clinical heterogen-
eity in systematic reviews.
Inclusion criteria
Clinical heterogeneity is defined as differences in partici-
pant, treatment, or outcome characteristics or research
setting. We included any methodological study, system-
atic review, guideline, textbook, handbook, checklist,
scale, or other published guidance document with a
focus on assessing, measuring, or generally investigating
clinical heterogeneity between or within controlled clin-
ical trials included in systematic reviews. This included
quantitative, qualitative, graphical or tabular techniques,
suggestions or methods.
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Exclusion criteria
Systematic reviews of interventions for efficacy were
excluded.
Data extraction
A data extraction form was developed and piloted inde-
pendently by two individuals (JG, DM) on a random se-
lection of 10 included resources. Extractions were
checked for consensus and the form revised according to
the feedback provided. One person extracted information
for all included studies (JG) regarding why the authors
sought to assess clinical heterogeneity; what “criteria”
were used to assess clinical heterogeneity; how these
were developed; the definition of clinical heterogeneity
used by the authors; any graphical, tabular or other dis-
play/summary methods; statistical recommendations;
reported methods used; empirical validation performed
on the “criteria”; examples of implementing the methods;
and recommendations on how the assessments are to be
used in systematic reviews. All extractions were checked
for accuracy by another individual (DM).
Synthesis methods
We thematically grouped the retrieved resources, sug-
gestions or techniques (e.g., statistical versus qualitative
recommendations), described the recommendations,
highlighted any empirical support cited for each recom-
mendation, and made an overall summary of the
recommendations.
Assessment of method validation
Four individuals (JG, DM, JB, CB) met several times to
discuss how to rate the variety of resources retrieved.
These individuals came to a consensus that there were
several classes of resources that did not have any accepted
risk-of-bias assessment tools or instruments (e.g., text-
books, narrative reviews, learning guides, expert opinions).
Therefore instead, of assessing “risk of bias” of these arti-
cles, we chose to determine if specific methods have been
validated. Resources were considered validated if they had
a clear rationale or reported empirical evidence for that
recommendation (e.g., reference to previous empirical
work or a test of the method with empirical or simulated
data). One individual (JG) assessed the method of valid-
ation of each of these included resources.
Results
Our searches identified 2497 unique titles and abstracts;
after screening, 101 papers were included in the review
[17-117]. These resources included statistical papers,
456 full texts reviewed for inclusion
• 462 excluded due to being 
duplicates
• 1450 excluded due to being 
systematic reviews of 
interventions 
• 135 excluded due to not being 
on clinical heterogeneity
101 included
a. PubMed, HTA, Cochrane Methodology register (through Oct. 29, 
2010): N = 612 
b. EMBASE (1980 to Oct. 30, 2010): N = 930 
c. CINAHL (EBSCO) (1981 to Oct. 30, 2010): N = 188 
d. PubMed related-links for 3 references(16,20,66): N = 762 
e. CONSORT Database (Up to Oct 30th, 2010): N = 0 additional 
citations 
f. Text books: N = 5 
Total N = 2497 titles and abstracts reviewed 
• 12 not related to SRs of 
controlled trials 
• 2 not available 
• 1 duplicate 
• 340 excluded due to not 
offering suggestions related to 
clinical heterogeneity 
Expert contact: N = 5 unique papers 
Reference list review: N = 1 unique 
paper
Figure 1 Search and inclusion results.
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methodological reviews, narrative reviews, expert opi-
nions, learning guides, consensus-based guidelines and
textbooks. Figure 1 describes details of the search and
screening results. The very few disagreements on inclu-
sion were easily resolved through discussion. Sixty-four
(64.6%) of the resources (statistical, methodological, con-
sensus guideline resources) were assessed for validation.
Forty-one (64.1%) of these references were evaluated as
being sufficiently validated.
Table 1 describes some basic characteristics of the
included resources. The most common type of re-
source was statistical papers (42.4%), with narrative
reviews/expert opinion papers being the next most
common (29.3%). Most of the papers were published
in the 2000s (70.1%), and statistical methods for inves-
tigating clinical heterogeneity were the most frequent
types of suggestions across resources (73.7%). Table 2
reports a list of clinical variables suggested for investi-
gating clinical heterogeneity and the number and types
of resources suggesting each. General suggestions of
clinically related variables, without identification of
specific clinical covariates, were the most common
across all included resources. Most suggestions were
within distinct categories: participant level (e.g., age),
intervention level (e.g., dose), or outcome level (e.g.,
event type, length of follow-up) covariates. A number
of resources (N = 14) reported control event rate/base-
line risk as being a covariate worth investigating.
Table 3 lists recommendations regarding the process
of choosing clinical characteristics to investigate. Five or
more resources suggested the following: a priori choice
of clinical covariates (e.g., in the review protocol); look
at forest plots for trials that may contribute to hetero-
geneity and then look for clinical characteristics therein;
Table 1 Descriptive characteristics of included resources
that reported recommendations for investigating clinical
heterogeneity in systematic reviews of controlled clinical
trials (N= 101)
Descriptive Characteristics N1
Type of publication Statistical paper 44
Narrative review or
expert opinion
29
Methodological review 14
Consensus-based guideline 9
Textbook 5
Decade of publication 2000s 70
1990s 27
1980s 4
Guidance on statistical
methods
75
Clinical variables
(general2 or specific)
recommended
39
Process for choosing
clinical variables recommended
28
1. The number (N) of resources equals the percentage of resources since we
include 101 total resources.
2. The term “general” means that the resource listed the term “patient”,
“intervention”, or “outcome” as a category from which to consider covariates
without suggesting specific variables.
Table 2 Types of clinical covariates suggested across all
resources
General Category Specific
Covariate
Number of
Resources
Recommending1
Patient level General2 15
Age 7
Baseline severity 3
Sex/gender 4
Ethnicity 2
Comorbidities 2
Other disease features 2
Intervention level General 13
Dose 8
Duration 5
Brand 3
Co-interventions 3
Intensity 3
Timing 3
Route 2
Compliance 2
Others unique to the
intervention
2
Frequency 1
Comparator/control 1
Outcome level General 6
Event type 5
Length of follow-up 4
Outcome measure type 3
Outcome definition 3
Timing 2
Repeated outcome
measurements
1
Control event rate /
baseline risk
14
Research setting 4
Comparison conditions 3
Early stopping rules 1
Population risk 1
1. The number (N) of resources equals the percentage of resources since we
include 101 total resources.
2. The term “general” means that the resource listed the term “patient”,
“intervention”, or “outcome” as a category from which to consider covariates
without suggesting specific variables.
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Table 3 Recommendations regarding the methods of choosing or identifying clinical covariates for investigation and
interpretation of the findings
General Category of
Recommendation
Specific Recommendation Number of
Resources1
Citations
When to identify covariates
in the review process
A priori (e.g., in protocol) 17 76, 92,93,95, 100, 98, 18, 26, 39,
40, 30, 59, 29, 31, 46, 94, 114
How to find important
clinical covariates from
trial information
Looking at forest plots
(variation in point estimates/CI
overlap/ adding a
vertical line for levels of
some clinical variable)
6 92, 98, 93, 97, 98, 94
Proceed regardless of formal
testing of statistical
heterogeneity
5 35, 92, 97, 98, 29
Looking at L’Abbe plots 4 98, 45, 93, 98
Influence plot 3 98, 54, 85
Looking at summary tables 2 92, 24
Looking at funnel plots 2 49, 98
Use conceptual frameworks to
facilitate choice of covariates
(i.e., using taxonomies for
active ingredients)
2 98, 112
I2 (look at the change in
statistical heterogeneity by
adding subgroups)
2 87, 100
Plot of effect size against
individual covariates
1 48
Using an adaptation of
multidimensional
scaling (CoPlot)
1 55
Plot of normalized z-scores 1 93
Radial/Galbraith plot 1 93
Frequency distributions 1 98
Dose-response graph 1 3?
Use P.I.C.O. model to guide
choice of characteristics
1 115
Use causal mediating
processes
1 113
Treat strata within trials as
separate studies; these
subgroups if similar across
studies can be combined
1 46
Rationale for choice
of covariate
Scientific (e.g.,
pathophysiological,
pharmacologic argument)
10 7,76,92,93, 100, 18, 26, 59, 31, 115
Previous research
(e.g., large RCT)
3 76, 68, 100
Clinical grounds 2 96, 100
Indirect evidence 1 59
Personnel Use of clinical experts 2 21, 115
Blind to results of trials 1 35
Number of
covariates/
trials needed
Small number of covariates 7 92, 95, 100, 18, 26, 31, 94
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Table 3 Recommendations regarding the methods of choosing or identifying clinical covariates for investigation and
interpretation of the findings (Continued)
Each covariate investigation
should be based on an
adequate number of studies
(e.g., 10 for every moderator)
6 100, 59, 50, 94, 115
Investigators must report
actual number of covariates
investigated for reader to
determine the potential for
false-positives
1 115
Number of outcomes
to investigate
Restrict investigations to small
number of outcomes
(e.g., primary)
1 26
Limit to central question in
the analysis
1 94
Interpretation of results
of investigations
Use caution (4 resources note
especially with post hoc
testing)
12 100, 18, 29, 31, 85, 16, 20, 23, 25, 61, 32, 35
Observational only 6 59, 23, 94, 98, 100, 114
Exploratory or hypothesis
generating only
4 32, 100, 40, 94
Consider confounding
between covariates
4 100, 50, 115, 59
Consider artifactual causes of
between-study variation
2 6, 98
Consider biases (e.g.,
misclassification,
dilution, selection)
2 93, 115
Look at magnitude of the
effect and the 95% CI; not just
effect and p-value; consider
precision of the subgroup
effects (e.g., sample sizes in
the studies dictate precision of
the subgroup effects)
2 100, 115
Seek evidence to justify claims
of subgroup findings
1 26
Identify knowledge gaps in
the investigations
1 24
Consider effect of variability
within studies
1 19
Consider if the magnitude
is clinically important (i.e.,
differences in effect between
subgroups)
1 100
Think through causal
relationships, especially
directionality
1 113
Use caution with variables
grouped after randomization
1 23
Consider parabolic
relationships (i.e., beyond
linear regression)
1 115
Be cautious not to say there is
a consistency of effect if no
subgroup effects are found
1 115
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proceed with investigation regardless of results of formal
testing for statistical heterogeneity; base clinical covari-
ates on a clear scientific rationale (e.g., a pathophysio-
logical argument); investigate a small number of
covariates; base each covariate suggestion on an ad-
equate number of trials (e.g., 10 trials was a common
suggestion); use caution when interpreting the findings
of investigations; consider the results of such investiga-
tions as exploratory, hypothesis generating and observa-
tional; and consider confounding between covariates.
Table 4 summarizes the types of statistical methods
suggested for investigating clinical heterogeneity charac-
teristics and the number of resources suggesting each.
Many included resources made some mention of stat-
istical methods of investigating aspects of clinical het-
erogeneity (N= 69/99, 69.7%). Also, many of these
resources made general suggestions regarding the use of
subgroup analyses (N= 18) and meta-regression (N= 16);
however, the majority of these did not offer any specific
recommendations. A wide variety of meta-regression
techniques were suggested, many of which included
simulated evidence or other forms of empirical testing.
Several Bayesian approaches were suggested as well as
several methods for individual patient data analysis
[34,48,58,63,66,69,71,75,95]. Four textbooks appeared to
be relatively comprehensive in their treatment of statis-
tical recommendations [93-95,114].
Overall, we felt that there was some consensus across
the resources regarding planning investigations, the use
of clinical expertise, the rationale for choice of covariate,
how to think through types of covariates, making a cov-
ariate hierarchy, post hoc covariate identification, statis-
tical methods, data sources and interpretation of
findings (See Table 5). We summarize the common
recommendations that appeared in the literature to offer
some preliminary guidance for systematic reviewers in
Table 5 and we elaborate on several key areas in the dis-
cussion section below.
Sources appearing to be the most comprehensive in
their discussion of recommendations for investigating
clinical heterogeneity included the Cochrane Handbook
[100] and the Centre for Reviews and Dissemination’s
Guidance For Undertaking Reviews In Health Care [98]
and the AHRQ Comparative effectiveness review meth-
ods: clinical heterogeneity [115].
Discussion
A variety of decisions must be made when performing a
systematic review. One such decision is how to deal
with obvious differences among and within trials.
Though a significant test for the presence of statistical
heterogeneity (e.g., Q test) and a large degree of hetero-
geneity (e.g., I2 > 75%) might obligate a reviewer to look
for covariates to explain this variability, a nonsignificant
test or a small I2 (e.g., <25%) does not preclude the
need to investigate covariate treatment effect interac-
tions [35,92,97,100]. That is, even with low statistical
heterogeneity, there may still be factors that influence
the size of the treatment effect, especially if there is a
strong argument (i.e., pathophysiologic or otherwise)
that some variable likely does have such an influence.
Observed or expected heterogeneity of treatment
effects can be handled in several ways. The heterogeneity
can be ignored and a meta-analysis conducted with a
fixed-effects or random-effects model, or one can at-
tempt to explain the heterogeneity through subgroup
analyses, meta-regression or other techniques [25]. The
latter moves the review away from overall statements of
evidence to increasingly clinically applicable results and
conclusions as well as new hypotheses for future re-
search [75]. Anello and Fleiss [28] make a clear distinc-
tion between meta-analyses with a goal of arriving at a
Table 3 Recommendations regarding the methods of choosing or identifying clinical covariates for investigation and
interpretation of the findings (Continued)
Descriptive methods Perform a narrative synthesis
of these investigations
4 115, 98, 27, 100
Other: 1. idea webbing, 2.
qualitative case descriptions, 3.
investigator/methodological/
conceptual triangulation
1 98
Use of types of data Aggregate patient data for trial
level covariates
4 23, 25, 118, 46
Only group characteristics
derived prior to randomization
(e.g., stratifying)
2 23, 46
Individual patient data for
participant level covariates
1 59
Individual patient data only for
all covariates where possible
1 59
1. The number (N) of resources equals the percentage of resources since we include 101 total resources.
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Table 4 Statistical suggestions for investigating aspects of clinical heterogeneity
General Category of
Statistical Method
Specific Method Suggested Number of
Resources1
Citations
Subgroup analyses General 18 60, 2324, 25,46, 48, 50, 75, 92, 94,
93, 27, 97, 100, 98, 115, 105, 19
Hierarchical testing procedure
based on the heterogeneity
statistic Q
1 114
Combining subgroups across
studies (i.e., in stratified
studies)
1 114
Moderator Analyses
1. ANOVA2 analogue
(e.g., a categorical moderator)
4 48, 94, 95, 114
2. Meta-regression General mention 16 19, 60, 6, 24, 2528, 31,32,43, 50,
75, 94, 95, 100, 98, 93, 1325, 418
Fixed effects model (general) 4 92, 93, 94, 95
Bayesian models (general) 4 66, 71, 124, 95
New maximum likelihood
method
2 60, 124
New weighted least squares
model
2 58, 67
Random effects model
(general)
2 67, 114
Random effects model for IPD3 2 58, 61
Permutation-based resampling 2 31, 43
Other nonparametric (e.g.,
fractional polynomials, splines)
2 69, 85
Mixed effects model 2 38, 114
New variance estimators
(for covariates)
2 77, 84
Methods for measurement of
residual errors
2 59, 41
Bayesian model in the
presence of missing study-
level covariate data
1 110
Semi-parametric modeling
(general)
1 80
Fixed effects generalized least
squares model
1 68
Hierarchical regression models 3 60, 64, 124
Random effects model with
new variance estimator
1 70
Logistic regression with binary
outcomes
1 25
Interaction term for meta-
regression model
1 95
Consider nonlinear
relationships (e.g., use
quadratic or log
transformations)
1 48
Bayesian model for use in
meta-analyses of multiple
treatment comparisons
1 111
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common summary estimate of effect (“analytic meta-
analyses”) and those focused on explaining why the ef-
fect sizes vary (“exploratory or causal meta-analyses”).
The choice between these depends on the objective of
the review, but it is clear that meta-analyses are more
applicable to decision making (e.g., clinical, policy) when
they are exploratory in nature [14,28,53,75,99]. The trials
included in a systematic review may be so very similar
that the summary effect estimate is the most reasonable
and applicable metric [114]. But these cases are very
rare, and therefore we would expect most questions
asked and tested through meta-analytic methods should
concern possible reasons for variation in effect [114].
Many resources were found that suggested methods
for carrying out investigations of clinical heterogeneity
in systematic reviews [17-102]. There was great variety
in the types of resources identified (statistical papers to
commentaries) and in their potential for risk of bias. It
was decided early to include any resource, no matter the
design, methods, or publication type. For this reason
many of the included resources might normally be con-
sidered at a high risk of bias (e.g., narrative reviews, ex-
pert opinions, learning guides and commentaries) and
thus providing suggestions of questionable validity. But
it was felt that these types of resources might provide
the most valuable information on the subject of clinical
heterogeneity. That is, investigating, and in particular
choosing which clinical characteristics to investigate,
requires clinical expertise, or at a minimum, knowledge
of empirical evidence of some covariate of importance.
The inclusion of these resources could be viewed as a
drawback, but we saw it as a strength of this research. It
Table 4 Statistical suggestions for investigating aspects of clinical heterogeneity (Continued)
3. Multivariate analyses 1 48
4. Multiple univariate analyses
with Bonferroni adjustments
1 48
5. Meta-analysis of interaction
estimates
1 61
6. Model to include the
repeated observations
(time as a variable) using IPD
1 109
7. Z test 1 125
Bayesian Approaches
1. Hierarchical Bayesian
modeling
2 44, 48
2. Random effects models 1 63
Data Specific Approaches
1. IPD analyses General 5 75, 76, 95, 97, 23
Regression 1 61, 46
Adding a treatment-
covariate interaction term
1 95
2. Combination of IPD & APD4 Two-step models 2 74, 78
Multi-level model 2 69, 100
Meta-analysis of
interaction estimates
1 61
Other Approaches
Models for control event rate /
baseline risk
General (e.g., control
event rate)
10 63, 24, 71, 81, 79, 93, 100, 19, 78, 111
Structural equation modeling
(SEM)
Integration of SEM with fixed,
random and mixed effects
meta-analyses
1 42
Mixed treatment comparisons
combined with
meta-regression
1 72
Combining regression
coefficients from
separate studies
1 64
1. The number (N) of resources equals the percentage of resources since we include 101 total resources; 2. ANOVA= analysis of variance; 3. IPD = individual patient
data; 4. APD= aggregate patient data.
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was these resources that provided most of the sug-
gestions regarding the methods for choosing or iden-
tifying clinical covariates to investigate (Table 3). The
consensus-based guidelines provided most of the sugges-
tions regarding the process of choosing or identifying
clinical covariates, and the statistical papers, as might be
expected, covered the majority of the specific statistical
suggestions; but the textbooks also offered many sugges-
tions in both areas. There was some consensus across
resources, but only a small number of resources
included a relatively comprehensive set of recommenda-
tions [15,93,94,98]. Therefore, future research should be
directed at developing a comprehensive and up to date
set of guidelines to aid reviewers in investigating clinical
heterogeneity. We summarize the common recommen-
dations that appear in the literature to offer some pre-
liminary guidance for systematic reviewers (Table 5).
We were surprised to see that the term clinical hetero-
geneity was relatively commonly used and consistently
defined. We took our definition from several publica-
tions with which we were previously familiar [1,3]. In
some of the resources the term methodological hetero-
geneity was used synonymously with clinical heterogen-
eity, or clinical heterogeneity was considered to be one
component of methodological heterogeneity. While this
was infrequent in the literature, methodological aspects
of heterogeneity include but go beyond clinical aspects
or reasons for heterogeneity between trials. Thus, when
describing reasons for heterogeneity that are related to
the participants, intervention, outcomes or settings of
the trial, these should be termed clinical aspects of het-
erogeneity. A consistency of terminology is mandatory
for development of thought and investigation in this
area. With terminology in place, the discussion can
move to our recommendations.
When planning investigations of clinical heterogeneity
in systematic reviews of controlled trials one should
make such plans explicit, a priori, in the protocol for the
review. We would suggest that protocols be published or
registered in appropriate databases [118]. Next, it is rea-
sonable and arguably beneficial, when organizing the re-
view team, to include clinical experts or at a minimum,
state a plan for consulting clinical experts during par-
ticular phases of the review (e.g., when choosing clinical
covariates or during interpretation of findings). Further-
more, a set of clinical covariates should be chosen that
have a clearly stated rationale for their importance (e.g.,
pathophysiological argument or reference to the results
of a previous large trial). Review teams should think
through the following categories to determine if related
covariates might logically influence the treatment effect
in their particular review: participant level, intervention
level, outcome level, research setting, or others unique
to the research question. Several resources offered
Table 5 Summary of recommendations for investigating
clinical heterogeneity in systematic reviews
Recommendation Category Recommendation Description
A-priori planning 1. All plans for investigating clinical
heterogeneity should be made explicit,
a-priori (e.g., in the protocol for the
systematic review).
Clinical expertise 2. The review/investigative team should
include clinical experts or state a plan
for consulting clinical experts during the
review protocol development and
implementation (e.g., when choosing
clinical covariates and when
interpreting the findings).
Covariate rationale 3. Clinical covariates should be chosen
that have a clearly stated rationale for
their importance (e.g., a
pathophysiological argument, reference
to the results of a previous trial).
Thinking through
covariate categories
4. Review teams should think through
the following categories to determine if
related covariates might logically
influence the treatment effect in their
particular review: participant level,
intervention level, outcome level,
research setting, or others unique to
their research question.
Covariate hierarchy 5. A logical hierarchy of clinical
covariates should be formed and
investigated only if there is sufficient
rationale and a sufficient number of
trials available (10 trials per covariate).
Post hoc covariate
identification
6. State any plans to include additional
covariates after looking at the data
(post hoc) from included studies (e.g.,
forest plots, radial plots) and how they
plan to do this.
Statistical methods 7. Describe a-priori the statistical
methods proposed to investigate
identified covariates. Refer to accepted
texts or published papers in the area to
be sure to implement these methods in
a valid manner. Include an individual
with experience in conducting these
analyses.1
Data sources 8. Aggregate patient data: Reasonable
for investigating trial level covariates
9. Individual patient data: Consider
when investigating participant level
covariates (otherwise results are subject
to ecologic bias)
Interpretation 10. A. Protocol: Describe how the results
of any findings are going to be
interpreted and used in the overall
synthesis of evidence.
B. Review: Consider the observational
nature of these investigations; consider
confounds and important potential
biases; consider magnitude of the
effect, confidence intervals and
directionality of the effect.
1 We do not provide detailed recommendations for statistical analyses here
because of the breath and complexity of this topic. Instead we suggest that
one refer to accepted resources and well-trained individuals with expertise in
the area.
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conceptual mapping, idea webbing and causal modeling
as possible methods for identifying important covariates
and relationships between them [98,112,113]. Next, a
hierarchy of clinical covariates should be formed and
covariates investigated only if there is sufficient rationale
and later a sufficient number of trials available. That is,
covariates deemed more important than others on the
basis of an explicitly stated rationale should be immedi-
ately included in such investigations, with other covari-
ates being included when the number of trials is
sufficient. A generally accepted rule of thumb is that 10
events per predictor variable (EPV) maintains bias and
variability at acceptable levels. This rule derives from 2
simulation studies carried out for logistic and Cox mod-
eling strategies [119-121] and has been adapted to meta-
regression [1,114]. Therefore, it has been suggested that
for each covariate there should be at least 10 trials to
avoid potentially spurious findings [15]. Also, investiga-
tors should describe any plans to include additional
covariates after looking at the data from included stud-
ies (e.g., forest plots). This might include an examin-
ation of summary tables or various types of plots
[92,93,97,98,106], and it would be reasonable to include
the clinical expert(s) at this stage to aid in the interpret-
ation of the plotted data. Finally, how the results of any
findings are going to be interpreted and used in the
synthesis methods of the review needs to be explained.
Most resources advise caution in interpreting these
investigations, noting their exploratory nature, but when
there is a clearly stated rationale, especially when
derived from previous research, and sufficient trials are
included, a priori planned investigations may improve
applicability. Also, it was frequently suggested that the
interpretation of the results of these investigations
should consider confounds and important potential
biases, the magnitude of the effect, confidence intervals
and the directionality of the effect. Following these
recommendations may lead to valid and reliable investi-
gations of clinical heterogeneity and could improve
their overall applicability and lead to future research
that might test hypothesized subgroup effects.
A wide variety of statistical analyses are available for
investigating clinical heterogeneity in systematic reviews
of controlled clinical trials, and it is not within the
scope of this paper to cover these in detail. Other
resources cover this subject very well [15,93,95,100,114].
The sophistication of techniques is constantly growing,
and an updated, precise summary of such methods is
needed. Instead we will describe three available options
frequently suggested by resources included in our re-
view—subgroup analyses, meta-regression and the
analogue to the analysis of variance (ANOVA)—and
comment upon methods for exploring control group
event rate.
Subgroup analyses involve separating trials into groups
on the basis of some characteristic (e.g., intervention
dose) and then performing separate meta-analyses for
each group. This test provides an effect estimate within
subgroups and a significance test for that estimate; it
does not provide a test of variation in effect due to cov-
ariates. The greater the number of significant tests per-
formed, the greater the likelihood of type 1 errors. There
are some suggestions in the literature for how to control
for this (e.g., Bonferroni adjustments [48]). To test for
differences between subgroups a moderator analysis
must be done. Moderator analyses include meta-
regression and the analogue to the ANOVA, among
other techniques (e.g., Z test [114]). Meta-regression is
used to assess the impact of one or more independent
variables (e.g., age or intervention dose) upon the
dependent variable, the overall treatment effect [62]. In-
dependent variables may be continuous or categorical,
the latter expressed as a set of dummy variables with
one omitted category. Several modeling strategies are
available for performing meta-regression [100,108,122].
The results of meta-regression indicate which variables
influence the summary treatment effect, how much the
summary effect changes with each unit change in the
variable and the p-value of this influence. It has been
suggested that at least 10 trials per covariate are needed
to limit spurious findings, due to the low statistical
power of meta-regression, and a nonparametric test has
been suggested when this tenet is not fulfilled [30] Also,
one needs to consider the problems associated with eco-
logical bias when performing meta-regressions on pa-
tient levels variables [40]. Finally, the analogue to the
ANOVA examines the difference in the effect between
categorical levels of some variable using identical statis-
tical methods as a standard ANOVA [94].
The literature suggests many methods for examining
the influence of the control event rate or baseline risk,
which is considered an aggregate measure of known
(e.g., age and disease severity) and unknown variables
[15,43,93]. It has been argued that these examinations
provide little import to clinical practice since the influ-
ence of any possible causative variables is aggregated
and therefore the effect of individual covariates is un-
known [15]. Also, the influence of the control event rate
on the summary affect is affected by regression to the
mean, and sophisticated statistical procedures are
required to deal with this [15,43,93].
Bayesian approaches to meta-regression and hierarch-
ical Bayes modeling, among other areas, appear to be
well represented in the literature [66,71,95], as well as
more general resources for Bayesian meta-analytic tech-
niques [95,123]. These methods are developing rapidly;
therefore, frequent summaries of these important tech-
niques are required as a resource to reviewers.
Gagnier et al. BMC Medical Research Methodology 2012, 12:111 Page 11 of 15
http://www.biomedcentral.com/1471-2288/12/111
Finally, we would like to note suggestions in the litera-
ture concerning the utility of aggregate patient data
(APD) versus individual patient data (IPD). Several
resources give general recommendations regarding use
of IPD when exploring characteristics that could be con-
sidered aspects of clinical heterogeneity [15,74-76,95,97].
Some empirical evidence supports these recommenda-
tions [40,66,124,125]. When IPD is available, it should
be used as a basis to investigate aspects of clinical het-
erogeneity at the patient level (e.g., demographic charac-
teristics) so as to avoid ecological bias associated with
summary APD. It is reasonable to use APD for trial-level
covariates (e.g., intervention characteristics) that can be
considered aspects of clinical heterogeneity. In addition,
there may be opportunities to strategically use APD to-
gether with IPD to avoid the significant, and sometimes
insurmountable, effort required to collect complete
IPD [71].
Finally, in relation to the suggestions above for includ-
ing clinical expertise in systematic reviews, we feel it is
the responsibility of each therapeutic discipline to create
a repository of variables to consider when exploring ef-
fect variation in systematic reviews. Such warehousing of
clinically important covariates would serve as an import-
ant resource, allowing systematic reviewers and clinical
trialists to explore nuances in treatment effect that
might inform clinical decision making, and allowing for
increased applicability of findings.
Conclusions
In summary, although many recommendations are
available for investigating clinical heterogeneity in sys-
tematic reviews of controlled clinical trials, there is a
need to develop a comprehensive set of recommenda-
tions for how to perform valid, applicable, and appro-
priate investigations of clinical covariates [7,14]. This
will improve the applicability and utilization of system-
atic reviews by policy makers, clinicians, and other de-
cision makers and researchers who wish to build on
these findings.
Appendix A: Search strategies
1. OVID searches
Medline (1950 to Oct 29th, 2010); Cochrane Method-
ology Register (Oct 29th, 2010) ; HTA (Oct 29th, 2010);
EMBASE (1980 to Oct 30th, 2010)
“(((clinical adj5 heterogeneity)) and (assessment or
checklist or guideline or guidelines or scale or criteria))”
Note: A slight variation in this strategy was used for
EMBASE, on the EMBASE specific search engine, for an
updated search we performed from January 1st 2009 to
October 30th, 2010. This was due to a change in the
available electronic resources.
2. CINAHL (EBSCO) (1981 up to October 30th, 2010):
“TX clinical N8 heterogeneity and TX ( assessment OR
checklist OR guideline OR guidelines OR scale OR cri-
teria )”
3. CONSORT database of methodological papers (up to
Oct 30th, 2010)
Manual search of all citations.
4. Related PubMed links for (completed on October 31st ,
2010):
Thompson SG. Why sources of heterogeneity in meta-
analysis should be investigated. BMJ. 1994;309:1351–5.
5. Related PubMed links for (completed on October 31st,
2010):
Higgins J, Thompson S, Deeks J, Altman D. Statistical
heterogeneity in systematic reviews of clinical trials: a
critical appraisal of guidelines and practice. Journal of
Health Services & Research Policy. Jan 2002;7(1):51–61.
6. Related PubMed links for: (completed on October 31st,
2010)
Schmid CH, Stark PC, Berlin JA, Landais P and Lau J.
Meta-regression detected associations between hetero-
geneous treatment effects and study-level, but not pa-
tient-level, factors. Journal of Clinical Epidemiology.
2004;57:683–97.
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